



Brazilian Journal of
OTORHINOLARYNGOLOGY

www.bjorl.org



ORIGINAL ARTICLE

Neonatal hearing screening in a low-risk maternity hospital in São Paulo state^{☆,☆☆}



Adriana Aparecida Tahara Kemp^{a,*}, Camila Ribas Delecrode^a,
Giovannna César da Silva^a, Fabiana Martins^b, Ana Cláudia Figueiredo Frizzo^c,
Ana Cláudia Vieira Cardoso^c

^a Human Communication Disorders, Faculdade de Filosofia e Ciências (FFC), Universidade Estadual Paulista (UNESP), Marília, SP, Brazil

^b Secretaria Municipal de Saúde de Marília, Marília, SP, Brazil

^c Speech Therapy Department, Faculdade de Filosofia e Ciências (FFC), Universidade Estadual Paulista (UNESP), Marília, SP, Brazil

Received 27 March 2014; accepted 14 October 2014

Available online 26 July 2015

KEYWORDS

Audiology;
Neonatal screening;
Hearing tests

Abstract

Introduction: The literature indicates that neonatal hearing screening should be universal, so a description of programs that adopt this recommendation is relevant.

Objective: To describe the results of newborn hearing screening and the profile of mothers and newborns attended to in a low-risk maternity setting, and to correlate the characteristics of this population with the results of transient evoked otoacoustic emissions.

Methods: A contemporary cross-sectional cohort study. The sample consisted of 670 infants and the procedures performed were audiological history, transient-evoked otoacoustic emissions (TEOAE), distortion product-evoked otoacoustic emissions (DPEOAE), and automated-brainstem auditory evoked potential (ABSAEP).

Results: The rate of success in this program was 98.5%, the failure rate was 0.62%, and that of non-attendance to finalize the diagnostic process, 0.93%. When correlating the variables studied with the results of transient evoked otoacoustic emissions, there was a significant negative correlation only for age of infant.

Conclusion: The program of this maternity hospital was effective and complies with national and international recommendations. The population consisted of young mothers with few

[☆] Please cite this article as: Kemp AAT, Delecrode CR, da Silva GC, Martins F, Frizzo ACF, Cardoso ACV. Neonatal hearing screening in a low-risk maternity hospital in São Paulo state. Braz J Otorhinolaryngol. 2015;81:505–13.

^{☆☆} Institution: Universidade Estadual Paulista “Júlio de Mesquita Filho”, School of Philosophy and Sciences, Marília Campus, SP, Brazil.

* Corresponding author.

E-mail: dri_kemp@hotmail.com (A.A.T. Kemp).

PALAVRAS-CHAVE

Audiologia;
Triagem neonatal;
Testes auditivos

pregnancy complications and healthy infants. The only variable that influenced transient evoked otoacoustic emission results, after hospital discharge, was the age at which infants were evaluated.

© 2015 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Published by Elsevier Editora Ltda. All rights reserved.

Triagem auditiva neonatal em uma maternidade de baixo risco do interior paulista

Resumo

Introdução: A literatura relata que a triagem auditiva neonatal deve ser universal, o que torna relevante a descrição de programas que adotam esta recomendação.

Objetivo: Descrever os resultados da triagem auditiva neonatal e o perfil das mães e recém-nascidos atendidos em uma maternidade de baixo risco e correlacionar as características desta população com os resultados das emissões otoacústicas evocadas transientes.

Método: Estudo coorte contemporâneo com corte transversal. A amostra foi composta por 670 bebês e os procedimentos realizados foram: anamnese audiológica, emissões otoacústicas (EOA) transientes, EOA produto de distorção, e potencial evocado auditivo de tronco encefálico automático.

Resultados: O índice de passa neste programa foi de 98,5%; de falha de 0,62% e o de não comparecimento para finalização do processo diagnóstico de 0,93%. Ao correlacionar as variáveis estudadas com os resultados das emissões otoacústicas transiente houve correlação negativa significativa apenas para a idade do bebê.

Conclusão: O programa desta maternidade mostrou-se efetivo e atende a recomendações nacionais e internacionais. A população foi composta por mães jovens com poucas intercorrências gestacionais e bebês saudáveis. A única variável que influenciou nos resultados das emissões otoacústicas por transiente, após a alta hospitalar, foi a idade em que os bebês foram avaliados.

© 2015 Associação Brasileira de Otorrinolaringologia e Cirurgia Cérvico-Facial. Publicado por Elsevier Editora Ltda. Todos os direitos reservados.

Introduction

The Universal Newborn Hearing Screening (UNHS) program seeks early detection of hearing loss, with the aim of evaluating the hearing ability of neonates with and without risk factors for hearing loss (RFHL). This process consists of performing behavioral, electroacoustic, and/or electrophysiological procedures to identify hearing loss.¹

Discussions about the importance and implementation of newborn hearing screening programs were initiated in the 1990s. In 2000, the Brazilian Speech Therapy Council issued an opinion indicating the need to implement hearing screening procedures in neonates using some objective methodology already described in the literature, such as recording evoked otoacoustic emissions and brainstem auditory evoked potential (BAEP).²

Several local and state laws have been passed in this country, making completion of the UNHS compulsory in maternity wards. Of note is National Law No. 12,303 of August 2, 2010, which determines the obligation to carry out evoked otoacoustic emission tests in all hospitals and maternity wards in children born on their premises.³ However, it is known that few public maternity facilities run a systematic universal newborn hearing screening program.⁴

The literature reports that the most widely used methods in newborn hearing screening programs are probably

the transient-evoked otoacoustic emission (T-EOAE) test in a first stage, and the auditory brainstem response in a second stage, for those infants who failed the T-EOAE test. The combination of both tests was designed to reduce the number of false-negative results, especially in cases of auditory neuropathy/dyssynchrony, in addition to improving the sensitivity and specificity of UNHS results.⁵⁻¹⁷

In reviewing the studies published in the Brazilian literature describing characteristics of newborn hearing screening programs, it is observed that most of them specify test results, gender, age, birth weight, and risk indicators. There have been numerous reports of screening results according to risk indicators.¹⁸⁻²⁸

Unlike articles published in the literature, the present study aimed to describe a newborn hearing screening program in which the majority of treated newborns had no risk indicators for hearing loss, which would decrease the incidence of hearing loss in this population. In addition, it was intended to expand the description of the characteristics commonly reported in the literature for mothers and newborns.

Considering the above, the aim of this study was to describe the results of a newborn hearing screening program and the profile of mothers and newborns attended in a low-risk maternity ward, as well as to correlate the




Figure 1 Flowchart. RFHL, risk factors for hearing loss; TEOAE, transient-evoked otoacoustic emissions; DPEOAE, distortion product-evoked otoacoustic emissions; A-ABEP, automated-auditory brainstem emission potential.

characteristics of this population with the results of transient evoked otoacoustic emissions.

Methods

This was a contemporary cohort cross-sectional study, performed in a maternity hospital in São Paulo State and approved by the Institution's Research Ethics Committee, under No. 0703/2013.

This maternity ward is part of the Unified Health System (SUS) and cares for low-risk pregnant women, with an average of 1500 births per year. The institution is part of *Rede Cegonha*, a program developed by the Ministry of Health that offer humanized care with the following objectives: (1) implementation of a new model of health care for women and children, with a focus on delivery, birth, growth, and development; (2) Organization of maternal and child health services; and (3) reduction of maternal and infant mortality in the neonatal period. In addition to this program, this maternity ward has partnership with the Human Milk Bank of the city of Marília, São Paulo, Brazil in order to educate mothers on the importance of exclusive breastfeeding and addressing any problem related to breastfeeding and collection, storage, and donation of breast milk.

As to the composition of this sample, the following inclusion and exclusion criteria were used: signing the informed consent, screenings conducted in the period from May to

November of 2013, and response of the mothers to anamnesis data.

Thus, this study was based on data from 670 newborns attended by this neonatal hearing screening program.

To achieve this goal, the following procedures were used: anamnesis, meatoscopy, and hearing tests (T-EOAE, distortion product-evoked otoacoustic emission [DP-EOAE], and automated-auditory brainstem emission potential [A-ABEP]).

Initially, an audiological history was obtained, based on a questionnaire (*Annex*) consisting of identification data, questions about gestational history, delivery, and newborn data, such as: gender, age, gestational time (preterm or term), mother's age, type of delivery (normal or cesarean), pregnancy complications, baby's birth weight, type of feeding, bottle feeding and/or pacifier use, and other risk factors for hearing loss,¹ including phototherapy for hyperbilirubinemia. It was decided in favor of the addition of this indicator, because of the high incidence of hearing loss in children undergoing phototherapy in clinical practice.

Hearing procedures were divided into two stages: test and retest. For the test, T-EOAE was carried out; in case of failure in this test, DP-EOAE was added. For retest, T-EOAE, DP-EOAE, and A-ABEP were performed.

The flowchart in *Fig. 1* describes in detail the hierarchy of steps in the second hearing screening, according to risk indicators.

In this program, the newborn was discharged from hospital and returned after about a week for hearing screening (test) and puerperal consultation. If the infant failed the test, a retest was scheduled to be performed in approximately 15 days. In the event of no attendance of the baby for the test or retest, the mother was contacted in order to schedule a new date.

It was considered that the baby passed the test when there were responses in both ears for the procedures performed.

It is noteworthy that in cases where newborns passed the hearing screening test and had no risk indicators for hearing loss, their parents received guidance about the typical of hearing and language development, and on how to proceed in case of any change in this development (*i.e.* a new assessment); then mother and baby were discharged. Newborns who passed the hearing screening test but showing risk indicators for hearing loss were referred for a monitoring program. In this program, the baby attended a consultation every two months during the first year of life, in order to evaluate and monitor its hearing and language development.

Infants who failed the hearing screening test were referred for a full hearing evaluation.

Evoked otoacoustic emission and automatic auditory brainstem evoked potential tests were carried out with the help of a hand-held AccuScreen® screener (Madsen), suitable for use in hearing screening programs. To capture the answers, an ear probe was coupled to the external ear of the newborn, preferably during physiological sleep, or when still and quiet. Before the procedures, an automatic calibration of the equipment was performed, which depended on the newborn's external auditory canal volume.

The transient evoked otoacoustic emissions were generated from a click-type stimulus (frequency range, 1.5–4.5 kHz) with intensity ranging between 45 and 60 dB HL. The minimum stability of the probe obtained during the test was 70%. For the analysis of results, the equipment counts response signal peaks; the presence of eight peaks was necessary to consider that the neonate passed the test.

The distortion product evoked otoacoustic emissions were generated from the presentation of a primary tone pair of different frequencies (F1 and F2) in a relationship $F2/F1 = 1.22$, in which F1 is the primary stimulus of lower frequency and F2 the primary stimulus of greater frequency; and the distortion product obtained will occur in a different frequency range. The stimuli were presented on two levels (L1/L2) of 60/50 dB SPL. For screening and analysis of the results, protocol 1 of the equipment was used, which evaluates the frequencies of 5, 4, 3, and 2 kHz, in this order. The test is completed when the newborn presents response in three frequencies (passed) or when it does not present response in two frequencies (failed).

The automatic brainstem auditory evoked potential test was conducted with the electrodes applied to vertex (active), zygoma (ground), and C7 vertebra (reference). For this purpose, Ambu® Neuroline 720 disposable electrodes were used. These devices were applied after skin cleaning with an abrasive paste (Nuprep®), ensuring 4 Ω of maximum impedance for the electrodes. The stimulation parameters were: click sequence stimulus at 35 dB nHL, sampling rate 16 Hz, click level of approximately 80 Hz, incoming bandwidth from 70 Hz to 4 kHz, and gain of 2000.

Table 1 Description of gender and age of infants who attended screening.

Characteristics	<i>n</i>	%
<i>Gender</i>		
Male	337	52.2
Female	308	47.8
<i>Age (days)</i>		
5–10	308	44.7
11–15	122	18.9
16–20	91	14.1
21–30	40	6.2
26–30	36	5.6
≥30	48	7.5

For response analysis, the “passed” result was established when a response to the stimulus was detected by the machine.

The results of this study were presented with the use of descriptive and inferential statistics. Spearman's correlation was applied to verify the relationship among variables: birth weight, gender, age, gestational time, type of delivery, complications during pregnancy, Apgar score at 1 and 5 min of life, risk indicators for hearing loss, and results of transient otoacoustic emissions. The significance level was set at 5% ($p \leq 0.05$).

It is noteworthy that the decision was made to correlate the variables only with the results of transient evoked otoacoustic emissions, since distortion product evoked otoacoustic emissions and automatic brainstem auditory evoked potentials were carried out only in infants that failed the transient otoacoustic emission test. The low number of children undergoing these procedures precluded the correlation.

Results

Throughout this study, 645 (96.3%) of 670 neonates born in the maternity attended to neonatal hearing screening tests. It was not possible to find and/or reschedule the 25 neonates who did not attend and, consequently, there is no information as to their hearing status.

The percentage of “passed” infants in this hearing screening program was 98.5% (635), of “failed” babies, 0.62% (four), and of non-attendance for completion of the diagnostic process, 0.93% (six). Among those babies who passed, 92.6% (588) were discharged and 7.4% (47) were referred for monitoring, due to the presence of some risk factor (Fig. 1).

Infants who failed were referred for diagnostic procedures, and their audiological evaluation results showed the presence of conductive-type hearing loss in all cases (three with bilateral and one with unilateral loss).

When analyzing the variable “age”, it was observed that 308 (47.75%) infants were submitted to our hearing screening program at 5–10 days of age; the mean time of assessment was 14 days. As to the variable “gender,” the attendance for both genders was similar (Table 1).

Regarding perinatal characteristics, it was found that most infants had had a normal (60.9%) at term (97.8%)

Table 2 Perinatal characteristics of babies screened in the program.

Characteristics	n	%
<i>Type of delivery</i>		
Normal	393	60.9
Cesarean	252	39.1
<i>Gestational age (weeks)</i>		
≤36	5	0.8
37–41	631	97.8
≥42	9	1.4
<i>Birth weight (grams)</i>		
<1500	0	0
≥1500 and <2500	20	3.1
≥2500 and <3000	145	22.5
≥3000 and <4000	457	70.8
≥4000	23	3.6
<i>Apgar 1 min</i>		
<4	1	0.1
5–7	54	8.4
8–10	590	91.5
<i>Apgar 5 min</i>		
≤4	0	0
5–7	3	0.5
8–10	642	99.5
<i>Presence of risk indicators</i>		
Yes	49	7.6
No	596	92.4
<i>Type of risk indicator</i>		
Hyperbilirubinemia (phototherapy)	27	55.1
Family history of hearing loss	14	28.6
Intensive care unit time of stay	4	8.1
Ototoxic drug use for more than five days	4	8.1
Congenital infections (syphilis and toxoplasmosis)	3	6.1
Craniofacial anomalies	1	2
Presence of syndromes	1	2
Blood transfusion (Rh incompatibility)	1	2

childbirth, with mean weight of 3248 g and with appropriate one- and five-minute Apgar scores (Table 2).

As for risk indicators for hearing loss, such occurrence was noted in a minority of infants (7.6%), with a mean of risk indicators/baby of 1.12; the most prevalent risk factor was hyperbilirubinemia treated with phototherapy (Table 2).

In the mothers' profile analysis, most were of the age group between 16 and 25 years (57.82%), did not smoke (89.5%), did not use alcohol or drugs (98.6%), and had no complications during pregnancy (72.5%). The most frequent gestational complication was urinary tract infection (Table 3).

By correlating the variables studied with the results of transient otoacoustic emissions, we observed only a

Table 3 Gestational profile of mothers of babies screened in the program.

Characteristics	n	%
<i>Age (years)</i>		
13–20	201	32.8
21–25	180	27.9
26–30	141	21.9
31–35	81	12.5
≥36	32	4.9
<i>Complications during pregnancy</i>		
Yes	177	27.5
No	468	72.5
<i>Type of complication</i>		
Urinary infection	138	78
Placental abruption	17	9.6
Hypertension	5	2.9
Diabetes	2	1.1
Thyroid	3	1.7
Depression	2	1.1
Anemia	4	2.2
Other	6	3.4
<i>Alcohol or drugs during pregnancy</i>		
Yes	9	1.4
No	636	98.6
<i>Smoking during pregnancy</i>		
Yes	68	10.5
Not	577	89.5
<i>Medication during pregnancy</i>		
Yes	159	24.6
No	486	75.4

significant negative correlation for infant's age: the higher the infant's age, the lower the "failed" rate (Table 4).

Discussion

The implementation of universal newborn hearing screening programs intends to minimize and/or prevent hearing impairment related deficits in language, social, emotional, and cognitive development of children, regardless of the presence of risk indicators.

In the literature reports it can be seen that, for a screening program to be considered universal, at least 95% of neonates must be evaluated.¹ Based on this index, it can be said that this program was universal, since it covered 96.3% of newborns in this maternity. Thus, the importance of universal screening in this maternity is reinforced by the fact that the majority of the population cared for is considered as at low risk for hearing loss.

A study conducted in South Africa showed that the prevalence of sensorineural hearing loss in newborns is approximately 1/3 in 1000 children with low risk for hearing loss.²⁹ In Brazil, studies report a prevalence of approximately 0.9% for hearing impairment, regardless of the presence of risk indicators,^{30,31} and that 50% of hearing loss cases are identified in children considered at low risk.^{1,32,33}

Table 4 Correlation among variables studied with the results of transient evoked otoacoustic emissions.

Variables	<i>n</i>	<i>r</i>	<i>p</i>
Gender vs. T-EOAE	645	0.063755	0.10573
Infant age vs. T-EOAE	645	−0.089318	0.023297 ^a
Maternal age vs. T-EOAE	645	0.066639	0.090831
Gestational time vs. T-EOAE	645	0.002615	0.947151
Type of delivery vs. T-EOAE	645	−0.049478	0.209505
Complications during pregnancy vs. T-EOAE	645	0.019603	0.619235
Smoking during pregnancy vs. T-EOAE	645	−0.02007	0.610904
Alcohol or drugs during pregnancy vs. T-EOAE	645	−0.047922	0.224215
Medication during pregnancy vs. T-EOAE	645	−0.012547	0.750441
Infant weight vs. T-EOAE	645	0.002036	0.958835
Apgar 1 min vs. T-EOAE	645	0.033942	0.389459
Apgar 5 min vs. T-EOAE	645	0.030352	0.441587
Presence of risk indicator vs. T-EOAE	645	−0.055109	0.162128

T-EOAE, transient-evoked otoacoustic emissions; *p*, significance level; *r*, correlation coefficient.

^a Statistically significant relationship.

Another fact observed in this study, related to its scope, is the low dropout rate, which corroborates the findings described in the literature.^{18,34} However, other studies have reported a high dropout rate as a major challenge for newborn hearing screening programs.^{35,36}

The fact that the hearing screening tests were performed on the babies on the day scheduled for puerperal consultation and the active search system conducted by the health workers of the Basic Health Units of the municipality are possible explanations for this low dropout rate.

The implementation of newborn hearing screening programs in this country, especially in maternities that serve people with a lower socioeconomic status, is confronted with many difficulties that hinder its efficiency, since the dropout rate of this population during the process of newborn hearing screening is very high. Included among the reasons for not attending to the recommended returns are a lack of information of parents about the causes and symptoms, and the impact of hearing loss on the overall development of the child, a prevalent idea among mothers that their children have no risk of suffering a hearing loss, and anxiety triggered by the knowing that their children are being tested.³⁶

By analyzing another indicator of effectiveness of the program, it was observed that the age group with highest concentration of screening tests performed was that of infants between the fifth and tenth day of life (mean, 12); this finding is consistent with the literature, which calls for screening tests in the first month of life.¹

The percentage of hearing loss found in our population was 0.62%. In the literature, lower and similar rates were found, ranging between 0.1% and 0.5%;^{18,22,36–38} but higher rates were also found, ranging between 1.8% and 3.44%.^{39–41} This variation may be due to the difference among populations studied and also among methodologies employed.

The percentage of children who failed and thus were referred for diagnosis was 1.7% – less than those 4% reported in the literature.^{1,42} By analyzing the use of transient otoacoustic emissions as an initial test, it was found that 95% of infants passed the exam. In the Brazilian literature, this percentage ranged from 85% to 96.78%; some of these

studies corroborate this finding, while others do not confirm it.^{19,40,43,44}

The findings of this study, including the effectiveness of the program and lack of sensorineural hearing loss, are justified by the fact that most of the evaluated babies showed no risk indicators for hearing loss, by the number of babies evaluated in the period and, finally, because the screening test was held in the same day of puerperal consultation, allowing the realization of several procedures on the same day and place.

Another aspect addressed by the authors was the characterization of mothers and babies that attended this program. It must be borne in mind that 32.8% of mothers in this study were aged 13–19 years, thus being classified as teenagers according to the World Health Organization.⁴⁵

One study reported that occurrence of pregnancy in this period is a consistent public health problem, because of the greater risk for the mother and her infant, in addition to its strong biological, psychological, and social impact. The risk of maternal death for women aged 15–19 years is twice the risk for women aged 20–24 years.⁴⁶ However, in this study there were few complications in this population.

Finally, by correlating these variables with the results of transient otoacoustic emissions, a significant negative correlation was noted only for the infant's age: the higher the age, the lower the failure rate. However, there was no correlation among other variables studied, including presence of risk indicators, with the results of the examination.

One study indicates that failure rates can vary from 5% to 20% when the screening procedure is performed with otoacoustic emissions during the first 24 h, falling to 3% when the test is held between 24 and 48 h after birth.⁴²

In Brazil, most services perform their neonatal hearing screening before discharging the infant; however, there is no rule indicating whether the test should be conducted during the first 24 h of life or at a later time, during the first 48 h of life. Thus, it remains unclear if the infant's life span affects the outcome of neonatal hearing screening tests.⁴⁷

With respect to the presence of risk factors for hearing loss, the literature confirms that there is no correlation between risk factors for hearing loss and the result of

neonatal hearing screening procedures;²⁶ however, it must be said that other studies found correlation between these variables.³⁷ The most common risk factor in this population was hyperbilirubinemia treated with phototherapy; this finding agrees with data in the literature.²⁷ This factor can compromise the newborn hearing ability, with inner ear and central auditory pathway injury.⁴⁸

Conclusion

The universal newborn hearing screening program implemented in this maternity ward was effective and meets national and international recommendations. As for the participants' profile, the population consisted of young mothers

with few alterations in their pre-, peri-, and post-natal periods, and with healthy infants. The only variable that influenced the results of transient otoacoustic emissions after hospital discharge was the age at which the infants were evaluated.

Funding source

This study was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo – FAPESP.

Conflicts of interest

The authors declare no conflicts of interest.

Annex.

Newborn hearing screening program

Mother name: _____ Age _____
 Baby's name: _____ BD: ____ / ____ / ____
 Gender () F () M Weight: _____ Apgar: ____ / ____
 Prenatal care: () yes () no.
 Received information on hearing characteristics in prenatal care: () yes () no.
 Complaints about hearing: () yes () no. Which? _____
 Do you think it is important to evaluate your child's hearing? () yes () no.
 Have you ever heard about neonatal auditory screening (*teste da orelhinha*)? () yes () no.
 Complications during pregnancy: () yes () no. Which? _____

Smoking during pregnancy () yes () no. How many cigarettes? _____
 Alcohol use during pregnancy: () yes () no. How much: _____
 Drugs during pregnancy: () yes () no. What: _____
 Gestational time: _____
 Delivery type: () normal () cesarean () forceps
 Breastfeeding: () exclusive () mixed () artificial
 Bottle feeding: () yes () no.
 Pacifier use: () yes () no.

Risk indicators for hearing change
 () Hearing loss family history. Who? _____
 () Inbreeding.
 () Congenital infections (rubella, syphilis, CMV, herpes, toxoplasmosis, HIV).
 In which month? _____
 () ICU stay
 () Craniofacial anomalies. What? _____
 () Hyperbilirubinemia () sunbathing () phototherapy () transfusion
 () Presence of syndromes. What? _____
 () Viral or bacterial meningitis
 () Ototoxins for more than five days (antibiotics, aminoglycosides, diuretics, chemotherapeutic agents)
 () Encephalopathy, hydrocephalus, peri-ventricular hemorrhage, head trauma
 () Seizures
 () Bronchopulmonary dysplasia, persistent pulmonary hypertension, or diaphragmatic hernia
 () Mechanical ventilation for a minimum of five days
 () Blood transfusion. Reason? _____

References

1. Joint Committee on Infant Hearing. Executive Summary of Joint Committee on Infant Hearing Year 2007. Position Statement: principles and guidelines for early hearing detection and intervention programs Internet. Available from: <http://www.jcih.org/ExecSummFINAL.pdf>
2. Conselho Regional de Fonoaudiologia – 2ª. Região São Paulo. Parecer do CFFa. n. 05/00, de 10 de junho de 2000. Aspectos pertinentes à Triagem Auditiva Neonatal (TAN). São Paulo: Conselho Regional de Fonoaudiologia – 2ª. Região São Paulo. Available from: <http://www.fonosp.org.br/legislacao/pareceres-do-cffa/parecer-do-cffa-n%C2%BA-0500/> [accessed 09.03.2012].
3. Brasil. Lei 12.303, de 02 de agosto de 2010. Dispõe sobre a obrigatoriedade de realização do exame denominado Emissões Otoacústicas Evocadas. Brasília; 2010. Available from: http://www.planalto.gov.br/ccivil_03/_Ato2007-2010/2010/Lei/L12303.htm
4. Tochetto TM, Vieira EP. Legislação brasileira sobre triagem auditiva neonatal. 1st ed. São Paulo: Pró-fono; 2006.
5. Silva DPC, Martins RHG. Análise das emissões otoacústicas transientes e dos potenciais evocados auditivos do tronco encefálico em neonatos com hiperbilirrubinemia. *Braz J Otorrinolaringol*. 2009;75:381.
6. Azevedo MF. Emissões otoacústicas. In: Figueiredo MS, editor. Conhecimentos essenciais para entender bem: emissões otoacústicas e BERA. São José dos Campos: Pulso Editorial; 2003. p. 35–83.
7. Borges CAB, Moreira LMO, Pena GM, Fernandes FR, Borges BCB, Otani BH. Triagem auditiva neonatal universal. *Arq Int Otorrinolaringol*. 2006;10:28–34.
8. Kunst LR, Didoné DD, Moraes SC, Escobar GB, Vaucher AV, Biaggio EPV, et al. Sociodemographic profile of mothers admitted to a service of newborn hearing screening. *Distúrb Comun*. 2013;25:328–35.
9. Matas CG. Medidas eletrofisiológicas da audição - audiometria de tronco cerebral. In: Carvalho RMM, editor. Fonoaudiologia: informação para a formação. Rio de Janeiro: Guanabara Koogan; 2003. p. 43–57.
10. Ito-Orejas JI, Ramirez B, Moraes D, Almaraz A, Fernandez-Calvo JL. Comparison of two-step transient evoked otoacoustic emissions (TEOAE) and automated auditory brainstem response (AABR) or universal newborn hearing screening programs. *Pediatr Otorrinolaringol*. 2008;72:1193–201.
11. Simonek MCS, Azevedo MF. Respostas falso-positivas na triagem auditiva neonatal universal: Possíveis causas. *Rev CEFAC*. 2011;13:292–8.
12. Bubbico L, Bartolucci MA, Broglio D. The newborn hearing screening in Italy. *It J Pediatr*. 2005;31:290–2.
13. De Capua B, Costantini D, Martufi C, Latini G, Gentile M, De Felice C. Universal neonatal hearing screening: The Siena (Italy) experience on 19.700 newborns. *Early Hum Dev*. 2007;83:601–6.
14. Lewis DR, Marone SAM, Mendes BCA, Cruz OLM, Nóbrega M. Comitê multiprofissional em saúde auditiva COMUSA. *Braz J Otorrinolaringol*. 2010;76:121–8.
15. Patel H, Feldman M, Canadian Paediatric Society, Community Paediatrics committee. Universal newborn hearing screening. *Paediatr Child Health*. 2011;16:301–5.
16. Gilbey P, Kraus C, Ghanayim R, Sharabi-Nov A, Bretler S. Universal newborn hearing screening in Zefat, Israel: The first two years. *Int J Pediatr Otorrinolaringol*. 2013;77:97–100.
17. Ghirri P, Liumbruno A, Lunardi S, Forli F, Boldrini A, Baggiani A, et al. Universal neonatal audiological screening: experience of the University Hospital of Pisa. *Rev Ital Pediatr*. 2011;37:16.
18. Barreira-Nielsen C, Neto HAF, Gattaz G. Processo de implantação de Programa de Saúde Auditiva em duas maternidades públicas. *Rev Soc Bras Fonoaudiol*. 2007;12:99–105.
19. Lima GM, Marba ST, Santos MF. Hearing screening in a neonatal intensive care unit. *J Pediatr*. 2006;82:110–4.
20. Amado BCT, Almeida EOC, Berni OS. Prevalence of deafness risk indicators in newborns in a São Paulo upcountry maternity hospital. *Rev CEFAC*. 2009;11:18–23.
21. Vieira EP, Miranda EC, Azevedo MF, Garcia MV. Occurrence of risk indicators for hearing loss over four years in a neonatal hearing screening program of a public hospital. *Rev Soc Bras Fonoaudiol*. 2007;12:214–20.
22. Mattos WM, Cardoso LF, Bissani C, Pinheiro MMC, Viveiros CM, Filho WC. Newborn hearing screening program implantation analysis at a University Hospital. *Braz J Otorrinolaringol*. 2009;75:237–44.
23. Barboza ACS, Resende LM, Ferreira DBC, Lapertosa CZ, Carvalho SAS. Correlation between hearing loss and risk indicators in a neonatal hearing screening reference service. *Audiol Commun Res*. 2013;18:285–92.
24. Oliveira JS, Rodrigues LB, Aurélio FS, Silva VB. Risk factors and prevalence of newborn hearing loss in a private health care system of Porto Velho, Northern Brazil. *Rev Paul Pediatr*. 2013;31:299–305.
25. Pereira PKS, Martins AS, Vieira MR, Azevedo MF. Programa de triagem auditiva neonatal: associação entre perda auditiva e fatores de risco. *Pró-Fono*. 2007;3:267–78.
26. Didoné DD, Garcia MV, Kunst LR, Vieira EP, Silveira AF. Correlação dos indicadores de risco para deficiência auditiva com a falha na triagem auditiva neonatal. *Saúde (Santa Maria)*. 2013;1:113–20.
27. Dantas MBS, Anjos CAL, Camboim ED, Pimentel MCR. Resultados de um programa de triagem auditiva neonatal em Maceió. *Braz J Otorrinolaringol*. 2009;75:58–63.
28. Griz SMS, Almeida e Silva AR, Barbosa CP, Menezes DC, Curado NRPV, Silveira AK, et al. Indicadores de risco para perda auditiva em neonatos e lactentes atendidos em um programa de triagem auditiva neonatal. *Rev CEFAC*. 2011;13:281–91.
29. Swanepoel D, Ebrahim S, Joseph A, Friedland PL. Newborn hearing screening in a South African private health care hospital. *Int J Pediatr Otorrinolaringol*. 2007;71:881–7.
30. Guimarães VC, Barbosa MA. Prevalence of auditory changes in newborns in a teaching hospital. *Int Arch Otorrinolaringol*. 2012;16:179–85.
31. Bevilacqua MC, Alvarenga KF, Costa OA, Moret AL. The universal newborn hearing screening in Brazil: from identification to intervention. *Int J Pediatr Otorrinolaringol*. 2010;74:510–5.
32. National Infant Hearing. Early identification of hearing impairment in infants and young children. NIH Consens Statement. 1993;11:1–24.
33. Durante AS, Carvalho RMM, Costa MTZ, Cianciarullo MA, Voegels RL, Takahashi GM, et al. Programa de Triagem Auditiva Neonatal: modelo de implementação. *Arq Otorrinolaringol*. 2004;8:56–62.
34. Korres SG, Balatsouras DG, Nikolopoulos T, Korres GS, Ferekidis E. Making universal newborn hearing screening a success. *Int J Pediatr Otorrinolaringol*. 2006;70:241–6.
35. Machado MS, Oliveira TMT, Cósier PL. Triagem auditiva neonatal universal: projeto piloto no Hospital Universitário de Santa Maria (RS) - Brasil. *Pró-fono*. 2002;14:199–204.
36. Onoda RM, Azevedo MF, Santos AMN. Neonatal Hearing Screening: failures, hearing loss and risk indicators. *Braz J Otorrinolaringol*. 2011;77:775–83.
37. Vohr B, Carty L, Moore P, Letourneau Q. The Rhode Island hearing assessment program: experience with statewide hearing screening. *W Pediatr*. 1998;133:353–440.
38. Sokol J, Hyde M. Hearing screening. *Pediatr Rev*. 2002;23:155–62.

39. Tiensoi LO, Goulart LMHF, Resende LM, Colosimo EA. Hearing screening in a public hospital in Belo Horizonte, Minas Gerais State, Brazil: hearing impairment and risk factors in neonates and infants. *Cad Saúde Pública*. 2007;23:1431–41.
40. Boscatto SD, Machado MS. Hearing screening of São Vicente de Paulo Hospital: survey data. *Rev CEFAC*. 2013;15:1118–24.
41. Gaffney M, Green DR, Gaffney C. Newborn hearing screening and follow-up: are children receiving recommended services. *Public Health Rep*. 2010;125:199–207.
42. Comitê Brasileiro Sobre Perdas Auditivas na Infância. Período Neonatal. Recomendação 01/99. *Jornal do CFFa*. 2000;5:3–7.
43. Françoze MFC, Fernandes JC, Lima MCMP, Rossi TRF. Improvement of return rates in a neonatal hearing screening program: the contribution of social work. *Soc Work Health Care*. 2007;3:179–90.
44. Rodrigues PAL, CarvalhoTSF, LaurisJRP, Schochat E. Results of a newborn hearing screening program in Cuiabá – Mato Grosso. *Brazil Rev Soc Bras Fonoaudiol*. 2011;16:454–8.
45. World Health Organization. Young people's health: a challenge for society. Geneva: World Health Organization; 1986.
46. Oliveira FC, Surita FG, Pinto e Silva JL, Cecatti JG, Parpinelli MA, Haddad SM, et al. Severe maternal morbidity and maternal near miss in the extremes of reproductive age: results from a national cross-sectional multicenter study. *BMC Pregnancy Childbirth*. 2014;14:77.
47. Ribas A, Cabral J, Gonçalves V, Gonçalves CGO. Newborn hearing screening program: the influence of the lifespan of newborns in the research of transient otoacoustic emissions. *Rev CEFAC*. 2013;15:773–7.
48. Almeida FS, Pialarissi PR, Alegre ACM, Silva JV. Emissões acústicas e potenciais auditivos evocados do tronco cerebral: estudo em recém-nascidos hiperbilirrubinêmicos. *Braz J Otorhinolaryngol*. 2002;68:851–8.